Skip to main content
Suzhou Fushilai Pharmaceutical Co., Ltd. logo

Suzhou Fushilai Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301258 ISIN · CNE1000058W2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 573 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301258

About Suzhou Fushilai Pharmaceutical Co., Ltd.

https://www.fuslai.com

Suzhou Fushilai Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and nutritional supplements. The company is recognized as a leading global producer of the Lipoic acid series, including Alpha Lipoic Acid and its derivatives. Its product portfolio also encompasses the Carnitine series and various specialty chemical intermediates. Fushilai operates advanced production facilities that adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse international clientele across the pharmaceutical, nutraceutical, and functional food sectors, focusing on high-purity ingredients for antioxidant support and metabolic health. By integrating chemical synthesis with biotechnological innovation, the firm maintains a competitive position in the global supply chain for specialized health ingredients.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is a formal announcement detailing the company’s 2025 annual equity distribution (dividend) implementation: it specifies the per‐share cash dividend amount, total distribution, record date, ex‐dividend date, tax treatment, and payment mechanism. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-05-22 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is an official announcement of the 2025 Annual General Meeting resolutions, detailing meeting logistics, attendance, and precise voting results on each proposal. It does not present financial statements itself, but discloses the outcomes of shareholder votes. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-14 Chinese
上海兰迪（苏州）律师事务所关于苏州富士莱医药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 89% confidence The document is a legal opinion letter (法律意见书) issued by Shanghai Landing (Suzhou) Law Firm regarding the legality of the 2025 annual shareholders’ meeting procedures, convening, attendance qualifications, and vote results. It does not itself present financial statements or serve as the AGM materials like presentations or minutes. Instead, it is an attestation/certification by an external law firm. Under the Certification Rule, any document that is primarily an officer (or legal) certification or attestation should be classified as a Regulatory Filing (RNS).
2026-05-14 Chinese
董事会审计委员会对会计师事务所2025年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the accounting firm for the fiscal year 2025. It discusses the audit firm's qualifications, the audit process, communication with management, and the issuance of an unqualified audit opinion on the company's 2025 financial statements. The document references the audit of the 2025 annual financial report and internal controls, and the approval of the 2025 annual report and financial statements by the audit committee. The content is focused on audit evaluation and oversight rather than the full annual report itself. The document length is 2183 characters, which is relatively short but contains substantive audit evaluation content. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit evaluation report and not the full Annual Report (10-K). FY 2025
2026-04-22 Chinese
2025年度非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 95% confidence The document is a special statement from an accounting firm (RSM 容诚) regarding non-operating fund occupation and other related party fund transactions for Suzhou Fushilai Pharmaceutical Co., Ltd. It references the audit of the company's 2025 financial statements and compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes a detailed summary table of related party transactions and fund occupation for the year 2025. It is not a full annual report or audit report by itself but a specialized audit-related statement focusing on related party transactions and fund usage, prepared as a supplementary disclosure for the annual report. The document is about audit findings and compliance with regulatory requirements on related party transactions, which fits the category of Audit Report / Information (AR). The document length is 2196 characters, which is short but contains substantive audit-related content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2025
2026-04-22 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "苏州富士莱医药股份有限公司2025年年度报告全文" which translates to "Suzhou Fushilai Pharmaceutical Co., Ltd. 2025 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the full fiscal year 2025, management discussion and analysis, corporate governance, financial statements, audit reports, and other comprehensive disclosures. The document references the fiscal period from January 1, 2025 to December 31, 2025, and includes audited financial figures, management commentary, and detailed business and industry analysis. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2025
2026-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.